Retinopathy telescreening policy
Defines medical necessity and coverage distinctions for retinal telescreening (digital retinal imaging) with manual or automated interpretation for detection, monitoring, and management of diabetic retinopathy for BlueCHiP for Medicare and Commercial products, including coding and billing guidance.
No material clinical/coverage changes
Coverage Summary
Defines medical necessity and coverage distinctions for retinal telescreening (digital retinal imaging) with manual or automated interpretation for detection, monitoring, and management of diabetic retinopathy for BlueCHiP for Medicare and Commercial products. Coverage stance is mixed: some uses are considered medically necessary while others are not. Target population: diabetic individuals. Effective date: 01/01/2021; Last review: 10/14/2020. Distinctions exist between BlueCHiP for Medicare and Commercial products with differing allowances and limitations.